睿知中国医院研究地图
候选清单

广州南方医科大学

南方医科大学南方医院

Nanfang Hospital

在本站收录的 53 种疾病中,这家医院列在其中 29 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

南方医科大学南方医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma33 篇牵头论文牵头 6 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma8 篇牵头论文牵头 4 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma127 篇牵头论文牵头 7 项开放试验
  4. 胃癌Stomach cancer127 篇牵头论文牵头 12 项开放试验
  5. 肝母细胞瘤Hepatoblastoma0 篇牵头论文
  6. 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
  7. 骨肉瘤Osteosarcoma6 篇牵头论文
  8. 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
  9. 神经母细胞瘤Neuroblastoma2 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma3 篇牵头论文
  11. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia8 篇牵头论文
  12. β 地中海贫血Beta thalassaemia21 篇牵头论文
  13. 血友病 AHaemophilia A9 篇牵头论文
  14. 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome1 篇牵头论文
  15. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder3 篇牵头论文
  16. 重症肌无力Myasthenia gravis1 篇牵头论文
  17. 烟雾病Moyamoya disease6 篇牵头论文
  18. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis7 篇牵头论文
  19. 特发性肺纤维化Idiopathic pulmonary fibrosis5 篇牵头论文
  20. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis6 篇牵头论文
  21. 脊髓性肌萎缩症Spinal muscular atrophy1 篇牵头论文
  22. 法布雷病Fabry disease2 篇牵头论文
  23. 杜氏肌营养不良Duchenne muscular dystrophy0 篇牵头论文
  24. Alport 综合征Alport syndrome0 篇牵头论文
  25. IgA 肾病IgA nephropathy5 篇牵头论文牵头 1 项开放试验
  26. 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
  27. 先天性膈疝Congenital diaphragmatic hernia1 篇牵头论文
  28. 先天性巨结肠Hirschsprung disease0 篇牵头论文
  29. 家族性腺瘤性息肉病Familial adenomatous polyposis2 篇牵头论文

未列出的收录疾病:脊索瘤、尤文肉瘤、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、血栓性血小板减少性紫癜、范可尼贫血、IgG4相关性疾病、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、庞贝病、白塞病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 33 篇,占 1.4%。

牵头论文
33
2021–2025 年
牵头试验
8
任何状态,ClinicalTrials.gov
牵头的开放试验
6
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 3320222023: 5520232024: 8820242025: 662025

广州有 23 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 8

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
    分期
    未注明
    开始
    2026-08
    登记号
    NCT07819656

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院广州

  2. 正在招募
    A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis
    分期
    未注明
    开始
    2024-03
    登记号
    NCT06287788

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院广州

  3. 正在招募
    Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
    分期
    未注明
    开始
    2024-02
    登记号
    NCT06307314

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院广州

  4. 正在招募
    A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
    分期
    未注明
    开始
    2024-04
    登记号
    NCT06308328

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院;另有 9 家列出的医院为研究中心上海、广州、成都、深圳、珠海、韶关

  5. 正在招募
    Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma
    分期
    不分期
    开始
    2023-10
    登记号
    NCT06017895

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院广州

  6. 正在招募
    Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2018-01
    登记号
    NCT03919552

    年龄 18 岁 至 64 岁(登记的条件)

    牵头:南方医科大学南方医院广州

  7. 正在招募
    Adebrelimab and Chemoradiotherapy in High-risk LANPC
    分期
    II期
    开始
    2024-07
    登记号
    NCT06349889

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 3 家列出的医院为研究中心厦门、广州、成都

  8. 正在招募
    Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2021-03
    登记号
    NCT04778956

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心中山、佛山、广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与转移放疗技术影像与人工智能
论文中的科室放疗科耳鼻喉/头颈外科
牵头的论文33
  1. The impact of different cervical planning target volume designs on efficacy and toxicity in nasopharyngeal carcinoma: a single-center retrospective study.2025BMC cancer免费全文
  2. Exosomal PD-L1 derived from hypoxia nasopharyngeal carcinoma cell exacerbates CD8+ T cell suppression by promoting PD-L1 upregulation in macrophages.2025Cancer immunology, immunotherapy : CII免费全文
  3. METTL14 Regulates the Expression of Genes Related to Interferon, Interleukin and MHC Class I in Nasopharyngeal Carcinoma Cells.2025Cancer medicine免费全文
  4. Comparative Analysis of Hearing Loss Induced by Cisplatin Versus Carboplatin in Locally Advanced Nasopharyngeal Carcinoma: Early to Mid-Term Findings.2025Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  5. CircTBCD/IGF2BP2 complex stabilizes IGF-1R mRNA in an m6A-dependent manner to promote bone metastasis in nasopharyngeal carcinoma.2025International journal of biological macromolecules
  6. A dynamic online nomogram for predicting nutritional risk in nasopharyngeal carcinoma patients after radiotherapy.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer免费全文
  7. VLDL and LDL Subfractions Enhance the Risk Stratification of Individuals Who Underwent Epstein-Barr Virus-Based Screening for Nasopharyngeal Carcinoma: A Multicenter Cohort Study.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  8. Construction and application of nasopharyngeal carcinoma-specific big data platform based on electronic health records.2024American journal of otolaryngology
  9. GSTM3 enhances radiosensitivity of nasopharyngeal carcinoma by promoting radiation-induced ferroptosis through USP14/FASN axis and GPX4.2024British journal of cancer免费全文
  10. Plasma Metabolic Profiles-Based Prediction of Induction Chemotherapy Efficacy in Nasopharyngeal Carcinoma: Results of a Bidirectional Clinical Trial.2024Clinical cancer research : an official journal of the American Association for Cancer Research免费全文
  11. A Preliminary Study on Transcriptional Regulation of SNP Site C-1888T in the Promoter Region of Human PLUNC Gene and Nasopharyngeal Carcinoma Susceptibility.2024Genetics research免费全文
  12. A novel EIF3C-related CD8+ T-cell signature in predicting prognosis and immunotherapy response of nasopharyngeal carcinoma.2024Journal of cancer research and clinical oncology免费全文
  13. ThermomiR-377-3p-induced suppression of Cirbp expression is required for effective elimination of cancer cells and cancer stem-like cells by hyperthermia.2024Journal of experimental & clinical cancer research : CR免费全文
  14. IGF-1R mediates crosstalk between nasopharyngeal carcinoma cells and osteoclasts and promotes tumor bone metastasis.2024Journal of experimental & clinical cancer research : CR免费全文
  15. Targeting Glutamine Metabolism through Glutaminase Inhibition Suppresses Cell Proliferation and Progression in Nasopharyngeal Carcinoma.2023Anti-cancer agents in medicinal chemistry
  16. Nomogram incorporating Epstein-Barr virus DNA and a novel immune-nutritional marker for survival prediction in nasopharyngeal carcinoma.2023BMC cancer免费全文
  17. Impact of sex on treatment-related adverse effects and prognosis in nasopharyngeal carcinoma.2023BMC cancer免费全文
  18. Assessment and management of radiation-induced trismus in patients with nasopharyngeal carcinoma: a best practice implementation project.2023JBI evidence implementation
  19. Systemic immune-inflammation index during treatment predicts prognosis and guides clinical treatment in patients with nasopharyngeal carcinoma.2023Journal of cancer research and clinical oncology免费全文
  20. Combination of smoking and Epstein-Barr virus DNA is a predictor of poor prognosis for nasopharyngeal carcinoma: a long-term follow-up retrospective study.2022BMC cancer免费全文
  21. Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA.2022BMC cancer免费全文
  22. CYLD deficiency enhances metabolic reprogramming and tumor progression in nasopharyngeal carcinoma via PFKFB3.2022Cancer letters
  23. Expression and Biological Functions of EPC1 in Nasopharyngeal Carcinoma.2021Archives of Iranian medicine
  24. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.2021BMC cancer免费全文
  25. Study on structured method of Chinese MRI report of nasopharyngeal carcinoma.2021BMC medical informatics and decision making免费全文
  26. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.2021Cancer medicine免费全文
  27. Foxq1 promotes metastasis of nasopharyngeal carcinoma by inducing vasculogenic mimicry via the EGFR signaling pathway.2021Cell death & disease免费全文
  28. Intense Diffuse Uptake of 68Ga-FAPI-04 in the Breasts Found by PET/CT in a Patient With Advanced Nasopharyngeal Carcinoma.2021Clinical nuclear medicine
  29. Epstein-Barr virus (EBV) encoded microRNA BART8-3p drives radioresistance-associated metastasis in nasopharyngeal carcinoma.2021Journal of cellular physiology
  30. Cancer-associated fibroblasts promote the survival of irradiated nasopharyngeal carcinoma cells via the NF-κB pathway.2021Journal of experimental & clinical cancer research : CR免费全文
  31. Protein tyrosine phosphatase receptor type D gene promotes radiosensitivity via STAT3 dephosphorylation in nasopharyngeal carcinoma.2021Oncogene免费全文
  32. Diffusion weighted imaging in submandibular gland sparing helical tomotherapy for nasopharyngeal carcinoma.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  33. Functional Study of Polymorphism 1888 C>T in the Promoter Region of Human PLUNC Gene.2021The American journal of the medical sciences
它在 ClinicalTrials.gov 上的全部试验(任何状态)15
  1. Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma正在招募NCT07819656牵头方2026-08 启动
  2. A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis正在招募NCT06287788牵头方2024-03 启动
  3. A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis正在招募NCT06308328牵头方2024-04 启动
  4. Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis正在招募NCT06307314牵头方2024-02 启动
  5. Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma正在招募NCT06017895牵头方不分期2023-10 启动
  6. Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma正在招募NCT03919552牵头方III期2018-01 启动
  7. A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.状态不明NCT05682703牵头方2022-12 启动
  8. Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma状态不明NCT04221516牵头方II期2020-01 启动
  9. Adebrelimab and Chemoradiotherapy in High-risk LANPC正在招募NCT06349889研究中心II期2024-07 启动
  10. Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma正在招募NCT04778956研究中心III期2021-03 启动
  11. Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images状态不明NCT05202626研究中心2021-12 启动
  12. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  13. Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma已完成NCT04823468研究中心不分期2021-07 启动
  14. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer已完成NCT03581786研究中心III期2018-10 启动
  15. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
PubMed 以外找到的论文(未计入)20
  1. A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.2025Journal of Clinical Oncology会议摘要
  2. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Research会议摘要
  3. Evaluation of PD-L1 expression status in nasopharyngeal carcinoma by 18F-FDG PET/CT radiomics analysis2025International Journal of Radiation Research论文
  4. A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning2024eLife预印本
  5. Author response: A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning2024eLife同行评议
  6. EGFR-Regulated EMT is a Driver of Vasculogenic Mimicry in Nasopharyngeal Carcinoma2023Journal on oncology论文
  7. Impact of radiotherapy for nasopharyngeal carcinoma on carotid stenosis risk: a meta-analysis2023Figshare数据集
  8. Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.2023Journal of Clinical Oncology会议摘要
  9. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  10. Additional file 2 of CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK2022Figshare数据集
  11. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  12. Additional file 3 of CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK2022Figshare数据集
  13. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  14. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  15. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  16. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  17. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  18. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  19. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  20. 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy2021Journal for ImmunoTherapy of Cancer会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。

牵头论文
8
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 1120232024: 1120242025: 112025

广州有 11 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)
    分期
    不分期
    开始
    2026-05
    登记号
    NCT07627347

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:南方医科大学南方医院广州

  2. 正在招募
    A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2025-04
    登记号
    NCT06843889

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院广州

  3. 正在招募
    Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2022-09
    登记号
    NCT05214222

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院广州

  4. 正在招募
    Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
    分期
    未注明
    开始
    2022-08
    登记号
    NCT05392413

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题分子标志物与基因早期发现与内镜
论文中的科室病理/检验科消化/肝病科放疗科

这些论文过半是实验室或动物研究。

牵头的论文8
  1. High Kin17 expression is correlated with metastasis and prognosis of esophageal squamous cell carcinoma.2025The International journal of biological markers
  2. Global burden of esophageal cancer attributable to high BMI in 204 countries and territories: 1990-2019.2024Thoracic cancer免费全文
  3. Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancer.2023Cell death & disease免费全文
  4. COX-2 strengthens the effects of acid and bile salts on human esophageal cells and Barrett esophageal cells.2022BMC molecular and cell biology免费全文
  5. High-throughput membrane-anchored proteome screening reveals PIEZO1 as a promising antibody-drug target for human esophageal squamous cell carcinoma.2022Cancer medicine免费全文
  6. Reticulocalbin3: A Ca2+ homeostasis regulator that promotes esophageal squamous cell carcinoma progression and cisplatin resistance.2022Cancer science免费全文
  7. Oesophageal squamous cell carcinoma-associated IL-33 rewires macrophage polarization towards M2 via activating ornithine decarboxylase.2021Cell proliferation免费全文
  8. Upregulated long non‑coding RNA LincIN promotes tumor progression via the regulation of nuclear factor 90/microRNA‑7/HOXB13 in esophageal squamous cell carcinoma.2021International journal of molecular medicine免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
  1. Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)正在招募NCT07627347牵头方不分期2026-05 启动
  2. A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma正在招募NCT06843889牵头方II期2025-04 启动
  3. Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma正在招募NCT05214222牵头方II期2022-09 启动
  4. Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody正在招募NCT05392413牵头方2022-08 启动
  5. Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma进行中,不再招募NCT06885814牵头方II期2024-06 启动
  6. Exploration and Verification of DNA Methylolation in Early Screening of Esophageal Cancer状态不明NCT03922230牵头方2019-03 启动
  7. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  8. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).已终止NCT04949256研究中心III期2021-07 启动
  9. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  10. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  11. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
PubMed 以外找到的论文(未计入)10
  1. A phase II trial of neoadjuvant chemotherapy combined with anti-angiogenesis therapy and immunotherapy for resectable stageII-IIIB esophageal squamous cell carcinoma.2025Journal of Clinical Oncology论文
  2. Comparative genomic analysis of tumor tissue and surgical margin distances in esophageal squamous cell carcinoma.2025Journal of Clinical Oncology论文
  3. FGF19-FGFR4 axis as the inaugural target for determining the efficacy of advanced esophageal cancer treatment.2024Journal of Clinical Oncology会议摘要
  4. Impact of positive tumor-informed margin and TP53 mutations on surgical outcomes in esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  5. Penpulimab plus chemotherapy with or without anlotinib as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ANSWER): A randomized, two-arm, clinical trial in progress.2023Journal of Clinical Oncology会议摘要
  6. 429. DETECTION OF MOLECULAR RESIDUAL DISEASE (MRD) USING MATCHED TUMOR-MARGIN SEQUENCING IN EARLY STAGE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagus论文
  7. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  8. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figshare数据集
  9. Abstract 2178: Spectrum of pathogenic germline mutations in Chinese esophageal squamous cell carcinoma patients through next-generation sequencing2021Cancer Research会议摘要
  10. Three Survival‐Related Genes of Esophageal Squamous Cell Carcinoma Identified by Weighted Gene Coexpression Network Analysis2021Complexity论文

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 127 篇,占 0.9%。

牵头论文
127
2021–2025 年
牵头试验
15
任何状态,ClinicalTrials.gov
牵头的开放试验
7
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 242420212022: 333320222023: 242420232024: 191920242025: 25252025

广州有 14 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 11

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
    分期
    II期
    开始
    2025-12
    登记号
    NCT07327788

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院广州

  2. 正在招募
    Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
    分期
    未注明
    开始
    2025-12
    登记号
    NCT07436845

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院广州

  3. 正在招募
    Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma
    分期
    未注明
    开始
    2024-07
    登记号
    NCT06623474

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:南方医科大学南方医院广州

  4. 正在招募
    Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
    分期
    未注明
    开始
    2024-09
    登记号
    NCT06864221

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:南方医科大学南方医院广州

  5. 即将招募
    Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
    分期
    II期
    开始
    2026-04
    登记号
    NCT07537777

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院广州

  6. 即将招募
    Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
    分期
    II期
    开始
    2026-06
    登记号
    NCT07565415

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院广州

  7. 邀请入组
    A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery
    分期
    未注明
    开始
    2024-09
    登记号
    NCT06647264

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:南方医科大学南方医院广州

  8. 正在招募
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    分期
    I/II期
    开始
    2026-05
    登记号
    NCT07547553

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、沈阳、福州、蚌埠、长春

  9. 正在招募
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
    分期
    I期
    开始
    2025-04
    登记号
    NCT06858813

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、广州

  10. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  11. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室放疗科消化/肝病科普外/肝胆胰外科影像/核医学科
牵头的论文127
  1. Three-dimensional multimodal imaging for predicting early recurrence of hepatocellular carcinoma after surgical resection.2026Journal of advanced research免费全文
  2. A Novel Diagnostic Algorithm for Subcentimeter Hepatocellular Carcinoma Utilizing Gd-EOB-DTPA-Enhanced MRI: Multicenter Development and Validation.2025Academic radiology
  3. Acute kidney injury is associated with liver-related outcomes in patients with hepatitis B virus infection: a retrospective cohort study.2025BMC nephrology免费全文
  4. The safety and feasibility of the "pan-gate theory" in laparoscopic liver resection through laennec's approach combined with "regional hepatic inflow occlusion" for hepatocellular carcinoma.2025BMC surgery免费全文
  5. Baicalin promotes anti-tumor immunity in hepatocellular carcinoma through HIF-1α/Lactate/CXCL9 axis.2025Biochemical pharmacology
  6. PD-1/PD-L1 blockade therapy in hepatocellular carcinoma: Current status and potential biomarkers.2025Biochimica et biophysica acta. Reviews on cancer
  7. BAIAP2L2 facilitates hepatocellular carcinoma progression and immune evasion of via targeting JAK1-mediated pathway and PD-L1 expression.2025Cancer gene therapy
  8. Histopathologic deep learning model for predicting tumor response to hepatic arterial infusion chemotherapy plus TKIs and ICIs in large hepatocellular carcinoma.2025Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  9. TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects.2025Cancer immunology, immunotherapy : CII免费全文
  10. SORT1 promote the metastasis and invasion of hepatocellular carcinoma via p38/β-catenin/ZEB1 signaling pathway.2025Cell death & disease免费全文
  11. Spermine synthase engages in macrophages M2 polarization to sabotage antitumor immunity in hepatocellular carcinoma.2025Cell death and differentiation免费全文
  12. Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B.2025Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  13. Association of daily sleep duration with risk of metabolic dysfunction-associated steatotic liver disease and adverse liver outcomes.2025Diabetes & metabolism
  14. The oncogenic role of BCL2L12 associated with immune status in the prognosis of human hepatocellular carcinoma.2025Die Naturwissenschaften
  15. Metabolomics and lipidomics predictor of survival in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy.2025Drug metabolism and disposition: the biological fate of chemicals
  16. The LUBAC subunit HOIL-1 promotes the progression of HBV-associated hepatocellular carcinoma independently of linear ubiquitination.2025Experimental & molecular medicine免费全文
  17. Integration of Bulk RNA and Single-Cell Analyses Reveal Distinct Expression Patterns of Anoikis-Related Genes and the Immunosuppressive Role of NQO1+ Macrophages in Hepatocellular Carcinoma.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  18. Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma.2025Frontiers in immunologyRCT免费全文
  19. Quantification of Fascin-1-Positive Extracellular Vesicles by Nanoflow Cytometry for Early Detection of Hepatocellular Carcinoma in Liquid Biopsy.2025International journal of medical sciences免费全文
  20. Antiangiogenic Treatment Facilitates the Abscopal Effect of Radiation Therapy Combined With Anti-PD-1 in Hepatocellular Carcinoma.2025International journal of radiation oncology, biology, physics
  21. Comparison of the efficacy and safety of TACE-HAIC-MTTs-ICIs and TACE-MTTs-ICIs in the hepatocellular carcinoma: a prognostic analysis based on the dynamic changes of serum AFP.2025International journal of surgery (London, England)免费全文
  22. Exploring the potential mechanisms of Jinglinzi powder in treating hepatocellular carcinoma based on LC-MS, network pharmacology, molecular docking, and experimental validation.2025Journal of pharmaceutical and biomedical analysis
  23. Preoperative plasma ceramide profiling coupled with machine learning accurately predicts recurrence of hepatocellular carcinoma after resection.2025Lipids in health and disease免费全文
  24. Low-Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma.2025Liver international : official journal of the International Association for the Study of the Liver免费全文
  25. Picropodophyllin induces ferroptosis via blockage of AKT/NRF2/SLC7A11 and AKT/NRF2/SLC40A1 axes in hepatocellular carcinoma as a natural IGF1R inhibitor.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  26. Dual-Targeting Peptide Assembly Probe for Precise Detection of Biomarkers of Circulating Tumor Cells in Hepatocellular Carcinoma.2025Small (Weinheim an der Bergstrasse, Germany)
  27. Spleen-dedicated stiffness measurement performed well to rule out high-risk varices in HBV-related hepatocellular carcinoma: Screening for high-risk varices in HCC.2024Alimentary pharmacology & therapeutics
  28. Evaluation of an artificial intelligence-based clinical trial matching system in Chinese patients with hepatocellular carcinoma: a retrospective study.2024BMC cancer免费全文
  29. Synthesis and preclinical evaluation of a novel probe [18F]AlF-NOTA-IPB-GPC3P for PET imaging of GPC3 positive tumor.2024Bioorganic chemistry
  30. DYNLL1 accelerates cell cycle via ILF2/CDK4 axis to promote hepatocellular carcinoma development and palbociclib sensitivity.2024British journal of cancer免费全文
  31. Renin-angiotensin system inhibitors and risk of hepatocellular carcinoma among patients with hepatitis B virus infection.2024CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne免费全文
  32. Endoplasmic Reticulum Stress Potentiates the Immunosuppressive Microenvironment in Hepatocellular Carcinoma by Promoting the Release of SNHG6-Enriched Small Extracellular Vesicles.2024Cancer immunology research
  33. Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma.2024Cancer immunology, immunotherapy : CII免费全文
  34. Identification of pyroptosis subtypes and prognosis model of hepatocellular carcinoma based on pyroptosis-related genes.2024Cancer medicine免费全文
  35. Two somatic mutations in the androgen receptor N-terminal domain are oncogenic drivers in hepatocellular carcinoma.2024Communications biology免费全文
  36. Effect of peripheral blood lymphocyte count on the efficacy of immunotherapy combined with TKI in the treatment of advanced liver cancer.2024Frontiers in immunology免费全文
  37. Lactylation signature identifies liver fibrosis phenotypes and traces fibrotic progression to hepatocellular carcinoma.2024Frontiers in immunology免费全文
  38. Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for HCC.2024Hepatology (Baltimore, Md.)
  39. Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients.2024Hepatology (Baltimore, Md.)
  40. The development of a novel zeolite-based assay for efficient and deep plasma proteomic profiling.2024Journal of nanobiotechnology免费全文
  41. Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma.2024Journal of translational medicine免费全文
  42. Relationship among serum 25-hydroxyvitamin D, fibrosis stage, genetic susceptibility, and risk of severe liver disease.2024Nutrition (Burbank, Los Angeles County, Calif.)
  43. Integrative radiomics analyses identify universal signature for predicting prognosis and therapeutic vulnerabilities across primary and secondary liver cancers: A multi-cohort study.2024Pharmacological research
  44. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma.2024Signal transduction and targeted therapy免费全文
  45. Identification of secretory pathway-related genes based on Random Forest algorithm to predict the prognosis and immunotherapy response of hepatocellular carcinoma.2024The journal of gene medicine
  46. Multiomics analyses and machine learning of nuclear receptor coactivator 6 reveal its essential role in hepatocellular carcinoma.2023Cancer science免费全文
  47. Hexokinase 2 confers radio-resistance in hepatocellular carcinoma by promoting autophagy-dependent degradation of AIMP2.2023Cell death & disease免费全文
  48. TUBB2B facilitates progression of hepatocellular carcinoma by regulating cholesterol metabolism through targeting HNF4A/CYP27A1.2023Cell death & disease免费全文
  49. Thermoresponsive hydrogel for transcatheter arterial chemoembolization of hepatocellular carcinoma.2023Chemical communications (Cambridge, England)
  50. ALKBH5-mediated m6 A demethylation of TIRAP mRNA promotes radiation-induced liver fibrosis and decreases radiosensitivity of hepatocellular carcinoma.2023Clinical and translational medicine免费全文
  51. H4-methylation regulators mediated epitranscriptome patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.2023Clinical epigenetics免费全文
  52. Radiomics signature based on CECT for non-invasive prediction of response to anti-PD-1 therapy in patients with hepatocellular carcinoma.2023Clinical radiology
  53. Safety and efficacy of postoperative adjuvant therapy with atezolizumab and bevacizumab after radical resection of hepatocellular carcinoma.2023Clinics and research in hepatology and gastroenterology
  54. Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors.2023Digestive diseases (Basel, Switzerland)
  55. Various ambient air pollutants, residential green spaces, fibrosis 4 scores, genetic susceptibility, and risk of severe liver disease.2023Ecotoxicology and environmental safety
  56. TRMT6 promotes hepatocellular carcinoma progression through the PI3K/AKT signaling pathway.2023European journal of medical research免费全文
  57. Noninvasive evaluation of neutrophil extracellular traps signature predicts clinical outcomes and immunotherapy response in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  58. T cell receptor and B cell receptor exhibit unique signatures in tumor and adjacent non-tumor tissues of hepatocellular carcinoma.2023Frontiers in immunology免费全文
  59. Targeting NAD+ metabolism of hepatocellular carcinoma cells by lenvatinib promotes M2 macrophages reverse polarization, suppressing the HCC progression.2023Hepatology international
  60. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retr2023International immunopharmacology
  61. Expression and prognostic signatures of m6A-related lncRNAs in hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  62. Biejiajian pill inhibits progression of hepatocellular carcinoma by downregulating PDGFRβ signaling in cancer-associated fibroblasts.2023Journal of ethnopharmacology
  63. N6-methyladenosine RNA methylation in liver diseases: from mechanism to treatment.2023Journal of gastroenterology
  64. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.2023Journal of hepatology
  65. HIGD2A silencing impairs hepatocellular carcinoma growth via inhibiting mitochondrial function and the MAPK/ERK pathway.2023Journal of translational medicine免费全文
  66. TRIM16 E121D variant affects the risk and prognosis of hepatocellular carcinoma by modulating the Wnt/β-catenin pathway.2023Molecular carcinogenesis
  67. Baicalin inhibits hepatocellular carcinoma cell growth and metastasis by suppressing ROCK1 signaling.2023Phytotherapy research : PTR
  68. Pien Tze Huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma.2023Scientific reports免费全文
  69. The phospholipid flippase ATP9A enhances macropinocytosis to promote nutrient starvation tolerance in hepatocellular carcinoma.2023The Journal of pathology
  70. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.2022Advances in experimental medicine and biology
  71. Machine-learning algorithms based on personalized pathways for a novel predictive model for the diagnosis of hepatocellular carcinoma.2022BMC bioinformatics免费全文
  72. A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironment.2022BMC cancer免费全文
  73. Clinical and imaging features preoperative evaluation of histological grade and microvascular infiltration of hepatocellular carcinoma.2022BMC gastroenterology免费全文
  74. Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.2022BMC infectious diseases免费全文
  75. NUPR1 contributes to radiation resistance by maintaining ROS homeostasis via AhR/CYP signal axis in hepatocellular carcinoma.2022BMC medicine免费全文
  76. Lamin B1 is a potential therapeutic target and prognostic biomarker for hepatocellular carcinoma.2022Bioengineered免费全文
  77. UBE2T-mediated Akt ubiquitination and Akt/β-catenin activation promotes hepatocellular carcinoma development by increasing pyrimidine metabolism.2022Cell death & disease免费全文
  78. A New Prognostic Strategy Based on four DNA Repair-Associated lncRNAs for Hepatocellular Carcinoma.2022Combinatorial chemistry & high throughput screening
  79. Identification of a Novel N7-Methylguanosine-Related LncRNA Signature Predicts the Prognosis of Hepatocellular Carcinoma and Experiment Verification.2022Current oncology (Toronto, Ont.)免费全文
  80. CT images-based 3D convolutional neural network to predict early recurrence of solitary hepatocellular carcinoma after radical hepatectomy.2022Diagnostic and interventional radiology (Ankara, Turkey)免费全文
  81. IVIM using convolutional neural networks predicts microvascular invasion in HCC.2022European radiology
  82. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.2022Frontiers in immunology免费全文
  83. Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells.2022Frontiers in immunology免费全文
  84. Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts.2022Frontiers in immunology免费全文
  85. Circulating HBV RNA: From biology to clinical applications.2022Hepatology (Baltimore, Md.)
  86. Exploring prognostic value and regulation network of PPP1R1A in hepatocellular carcinoma.2022Human cell
  87. Phosphotungstate Acid Doped Polyanilines Nanorods for in situ NIR-II Photothermal Therapy of Orthotopic Hepatocellular Carcinoma in Rabbit.2022International journal of nanomedicine免费全文
  88. An individualized cirrhosis screening strategy might be more cost-effective in the general population.2022Journal of hepatology
  89. COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma.2022Journal of hepatology
  90. A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.2022Journal of immunology research免费全文
  91. Downregulation of TUSC3 promotes EMT and hepatocellular carcinoma progression through LIPC/AKT axis.2022Journal of translational medicine免费全文
  92. TGF-β1 induced deficiency of linc00261 promotes epithelial-mesenchymal-transition and stemness of hepatocellular carcinoma via modulating SMAD3.2022Journal of translational medicine免费全文
  93. Short-term prognosis for hepatocellular carcinoma patients with lung metastasis: A retrospective cohort study based on the SEER database.2022MedicineRCT免费全文
  94. Serum SALL4 as a predictive biomarker for the prognosis of patients with hepatocellular carcinoma who underwent nonsurgical treatment.2022Medicine免费全文
  95. The effects of the interactions of STAT4 rs7574865 with HBV mutations on the risk of hepatocellular carcinoma.2022Molecular carcinogenesis
  96. An enhancer variant at 16q22.1 predisposes to hepatocellular carcinoma via regulating PRMT7 expression.2022Nature communications免费全文
  97. PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells.2022Oncogene免费全文
  98. Laparoscopic central hepatectomy using a parenchymal-first approach: how we do it.2022Surgical endoscopy
  99. CRIP1 suppresses BBOX1-mediated carnitine metabolism to promote stemness in hepatocellular carcinoma.2022The EMBO journal免费全文
  100. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy.2022The Journal of infectious diseases
  101. PPP2R5D promotes hepatitis C virus infection by binding to viral NS5B and enhancing viral RNA replication.2022Virology journal免费全文
  102. Tumor-feeding artery diameter reduction is associated with improved short-term effect of hepatic arterial infusion chemotherapy plus lenvatinib treatment.2022World journal of gastroenterology免费全文
  103. Identification of RNA binding protein interacting with circular RNA and hub candidate network for hepatocellular carcinoma.2021Aging免费全文
  104. Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy-authors' reply.2021Alimentary pharmacology & therapeutics
  105. DEAH-box polypeptide 32 promotes hepatocellular carcinoma progression via activating the β-catenin pathway.2021Annals of medicine免费全文
  106. Identification of a thirteen-gene signature predicting overall survival for hepatocellular carcinoma.2021Bioscience reports免费全文
  107. ACOX2 is a prognostic marker and impedes the progression of hepatocellular carcinoma via PPARα pathway.2021Cell death & disease免费全文
  108. Medical ozone induces proliferation and migration inhibition through ROS accumulation and PI3K/AKT/NF-κB suppression in human liver cancer cells in vitro.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  109. COMMD10 inhibits tumor progression and induces apoptosis by blocking NF-κB signal and values up BCLC staging in predicting overall survival in hepatocellular carcinoma.2021Clinical and translational medicine免费全文
  110. The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization.2021European radiology
  111. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.2021Frontiers in immunology免费全文
  112. High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection.2021Frontiers in immunology免费全文
  113. Increased hepatitis B virus quasispecies diversity is correlated with liver fibrosis progression.2021Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  114. Efficacy of sorafenib combined with transcatheter hepatic arterial chemoembolization in treating intermediate-advanced hepatocellular carcinoma.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  115. RNA-binding protein RBM6 acts as a tumor suppressor gene to inhibit the progression of hepatocellular carcinoma.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  116. Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.2021Journal of gastroenterology and hepatology免费全文
  117. eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway.2021Journal of translational medicine免费全文
  118. The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling.2021Metabolism: clinical and experimental
  119. NIR-absorbing Prussian blue nanoparticles for transarterial infusion photothermal therapy of VX2 tumors implanted in rabbits.2021Nanoscale
  120. Noninvasively visualize the expression of LAPTM4B protein using a novel 18F-labeled peptide PET probe in hepatocellular carcinoma.2021Nuclear medicine and biology
  121. LIMK1 nuclear translocation promotes hepatocellular carcinoma progression by increasing p-ERK nuclear shuttling and by activating c-Myc signalling upon EGF stimulation.2021Oncogene
  122. Small extracellular vesicles containing miR-30a-3p attenuate the migration and invasion of hepatocellular carcinoma by targeting SNAP23 gene.2021Oncogene
  123. In vitro and in vivo anti-metastatic effect of the alkaliod matrine from Sophora flavecens on hepatocellular carcinoma and its mechanisms.2021Phytomedicine : international journal of phytotherapy and phytopharmacology
  124. Wnt/β-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  125. Related Factors of Hepatocellular Carcinoma Recurrence Associated With Hyperglycemia After Liver Transplantation.2021Transplantation proceedings
  126. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.2021World journal of gastroenterology免费全文
  127. Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients.2020Frontiers in immunology免费全文
中文论文(未计入)23
  1. [Overexpression of parathyroid hormone-like hormone facilitates hepatocellular carcinoma progression and correlates with adverse outcomes].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  2. [SLC1A5 overexpression accelerates progression of hepatocellular carcinoma by promoting M2 polarization of macrophages].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  3. [Overexpression of ubiquitin-conjugating enzyme 2T induces radiotherapy resistance in hepatocellular carcinoma by enriching regulatory T cells in the tumor microenvironment].2024Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  4. [Dealcoholized red wine inhibits occurrence and progression of hepatocellular carcinoma possibly by inducing cell cycle arrest and apoptosis].2023Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  5. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and 2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  6. [Treat-all: challenges of partial response and low-level viremia].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  7. [Predictive value of aMAP risk score for early recurrence of small hepatocellular carcinoma after microwave ablation].2023Zhonghua nei ke za zhi
  8. [Pan-cancer analysis of the expression pattern of long non-coding RNA MIR22HG].2022Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  9. [TRIM21 suppresses invasion of hepatocellular carcinoma cells by promoting β-catenin ubiquitylation and degradation].2022Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  10. [Application of liquid biopsy in early screening and recurrence prediction of hepatocellular carcinoma].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  11. [Research advances of metabolomics in early diagnosis of hepatocellular carcinoma].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  12. [Multi-omics research contributes to early screening, diagnosis and treatment of liver cancer].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  13. [Study on the relationship between nonalcoholic fatty liver disease and hepatocellular carcinoma in patients with prior hepatitis B virus infection].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  14. [Antitumor effects of AZD2014, a dual mTORC1/2 inhibitor, against human hepatocellular carcinoma xenograft in nude mice].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  15. [Risk analysis for hepatocellular carcinoma in patients with chronic hepatitis B-associated cirrhosis complicated by type 2 diabetes mellitus: a 5-year prospective cohort study].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  16. [Long non-coding RNA UPK1A-AS1 promotes glycolysis in hepatocellular carcinoma cells via stabilization of HIF-1α].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  17. [Analysis of the effect of microwave ablation in the treatment of small liver cancer].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  18. [Regulatory effect of molecular targeted drugs on the immune system for liver cancer].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  19. [Higher proportion of hepatitis B-related hepatocellular carcinoma combined with metabolic diseases in patients receiving antiviral therapy].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  20. [Application of aMAP score to assess the risk of hepatocarciongenesis in population of chronic liver disease in primary hospitals].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  21. [Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  22. [Establishing an integrated hospital-community pyramid for screening and achieving hepatocellular carcinoma early diagnosis and treatment].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  23. [New progress in the diagnosis and treatment of hepatocellular carcinoma: a decade of grinding sword].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)57
  1. Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy即将招募NCT07537777牵头方II期2026-04 启动
  2. Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy即将招募NCT07565415牵头方II期2026-06 启动
  3. QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT正在招募NCT07327788牵头方II期2025-12 启动
  4. Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy正在招募NCT07436845牵头方2025-12 启动
  5. A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery邀请入组NCT06647264牵头方2024-09 启动
  6. Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma正在招募NCT06623474牵头方2024-07 启动
  7. Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma正在招募NCT06864221牵头方2024-09 启动
  8. Chemotherapy With the Ralox Regimen Combined With Anlotinib and Penpulimab for Unresectable Hepatocellular Carcinoma进行中,不再招募NCT07746960牵头方早期I期2025-01 启动
  9. Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer进行中,不再招募NCT07230080牵头方2024-09 启动
  10. Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma进行中,不再招募NCT05507632牵头方II期2022-08 启动
  11. Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma已完成NCT05003700牵头方II期2021-08 启动
  12. Carelizumab Combined With Regorafenib in the Treatment of HCC(CARE-2020)状态不明NCT04806243牵头方II期2021-05 启动
  13. Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC状态不明NCT05171309牵头方II期2021-01 启动
  14. Observational Study on Patients With Hepatocellular Carcinoma (HCC)状态不明NCT04021056牵头方2011-01 启动
  15. Novel Abdominal Compression Positioning Technique for Respiratory Motion Management in Liver Tumors已完成NCT07745153牵头方(推断)2025-01 启动
  16. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC正在招募NCT07547553研究中心I/II期2026-05 启动
  17. A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)正在招募NCT06858813研究中心I期2025-04 启动
  18. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  19. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  20. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)已终止NCT06487559研究中心I期2024-09 启动
  21. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)进行中,不再招募NCT05904886研究中心III期2023-09 启动
  22. A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC进行中,不再招募NCT05319431研究中心II期2022-06 启动
  23. Auxiliary Diagnosis of Liver Nodules Using cfDNA Whole-genome Signatures状态不明NCT05393102研究中心2022-05 启动
  24. A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification状态不明NCT05313282研究中心III期2022-06 启动
  25. A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)状态不明NCT05214339研究中心II期2022-03 启动
  26. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma已终止NCT05653427研究中心II期2022-12 启动
  27. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  28. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC已完成NCT04948697研究中心II期2021-08 启动
  29. A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab进行中,不再招募NCT04770896研究中心III期2021-04 启动
  30. Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)已完成NCT04740307研究中心II期2021-03 启动
  31. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  32. "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma状态不明NCT04317248研究中心II期2020-04 启动
  33. Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma已完成NCT04401800研究中心II期2020-09 启动
  34. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  35. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  36. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  37. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  38. Chimeric Antigen Receptor T Cells Targeting Glypican-3已完成NCT03884751研究中心I期2019-08 启动
  39. A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma已完成NCT04194801研究中心I/II期2019-12 启动
  40. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)已完成NCT03867084研究中心III期2019-05 启动
  41. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  42. Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation状态不明NCT03500848研究中心II/III期2018-05 启动
  43. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects已终止NCT03591965研究中心II期2018-08 启动
  44. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)已完成NCT03713593研究中心III期2018-12 启动
  45. Study of BGB-A317 in Participants With Previously Treated Unresectable HCC已完成NCT03419897研究中心II期2018-04 启动
  46. Prospective Surveillance for Very Early Hepatocellular Carcinoma状态不明NCT03588442研究中心2018-07 启动
  47. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma已完成NCT03434379研究中心III期2018-03 启动
  48. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  49. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects已终止NCT03236649研究中心III期2017-09 启动
  50. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects状态不明NCT03236636研究中心III期2017-09 启动
  51. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC已完成NCT03516071研究中心II期2017-05 启动
  52. STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma已完成NCT03113955研究中心不分期2017-10 启动
  53. HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China状态不明NCT02743065研究中心2016-09 启动
  54. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma已完成NCT02508467研究中心I期2015-07 启动
  55. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma已完成NCT01988493研究中心I/II期2014-01 启动
  56. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)已完成NCT00617981研究中心III期2008-05 启动
  57. T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients已终止NCT00057382研究中心II/III期2003-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 127 篇,占 1.3%。

牵头论文
127
2021–2025 年
牵头试验
29
任何状态,ClinicalTrials.gov
牵头的开放试验
12
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 222220212022: 303020222023: 171720232024: 282820242025: 30302025

广州有 16 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 17

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Correlation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric Cancer
    分期
    未注明
    开始
    2025-01
    登记号
    NCT07003334

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院广州

  2. 正在招募
    A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening
    分期
    未注明
    开始
    2025-06
    登记号
    NCT07032961

    年龄 45 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院广州

  3. 正在招募
    Novel Humanized Ferritin-Based NIR Fluorescent Probe for Identifying Sentinel Lymph Node Metastasis in Early Gastric Cancer
    分期
    未注明
    开始
    2025-07
    登记号
    NCT07294638

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院广州

  4. 正在招募
    Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
    分期
    II期
    开始
    2024-06
    登记号
    NCT06157996

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院广州

  5. 正在招募
    OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
    分期
    不分期
    开始
    2022-09
    登记号
    NCT05450835

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院;另有 7 家列出的医院为研究中心广州、汕头、沈阳、长春、长沙

  6. 正在招募
    Dual-Port Laparoscopic Distal Gastrectomy for Gastric Cancer
    分期
    不分期
    开始
    2022-08
    登记号
    NCT05494086

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院广州

  7. 正在招募
    Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.
    分期
    未注明
    开始
    2021-05
    登记号
    NCT04850729

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院广州

  8. 即将招募
    Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer
    分期
    II期
    开始
    2026-05
    登记号
    NCT07511894

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院广州

  9. 即将招募
    Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma
    分期
    II/III期
    开始
    2026-06
    登记号
    NCT07603349

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院广州

  10. 即将招募
    Novel Humanized Ferritin-based NIR Fluorescent Molecular Probe for Identifying Tumor Margins in Gastric Tissue
    分期
    未注明
    开始
    2025-12
    登记号
    NCT07276854

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院广州

  11. 即将招募
    Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
    分期
    II期
    开始
    2024-03
    登记号
    NCT06310473

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院广州

  12. 邀请入组
    An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma
    分期
    未注明
    开始
    2025-10
    登记号
    NCT07274579

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院;另有 1 家列出的医院为研究中心广州、济南

  13. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

  14. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙

  15. 正在招募
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    分期
    未注明
    开始
    2023-01
    登记号
    NCT05722275

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、太原、广州、昆明、福州、郑州

  16. 正在招募
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    分期
    未注明
    开始
    2023-09
    登记号
    NCT06035250

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛

  17. 正在招募
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    II期
    开始
    2023-11
    登记号
    NCT06155383

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、厦门、哈尔滨、广州、成都、昆明、济南、福州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期免疫与靶向药物影像与人工智能
论文中的科室普外/肝胆胰外科肿瘤内科消化/肝病科病理/检验科
牵头的论文127
  1. Bimodal In Situ Analyzer for Circular RNA in Extracellular Vesicles Combined with Machine Learning for Accurate Gastric Cancer Detection.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Artificial Intelligence for Predicting HER2 Status of Gastric Cancer Based on Whole-Slide Histopathology Images: A Retrospective Multicenter Study.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Disitamab vedotin plus programmed death-1 inhibitor for pre-treated HER2 overexpressed advanced gastric cancer: a multicentre retrospective real-world study.2025Annals of medicine免费全文
  4. Conversion Surgery After Trastuzumab-Based Chemotherapy and Immunotherapy for Stage IV HER2-Positive Gastric Cancer: A Retrospective Multicenter Cohort Study.2025Annals of surgical oncology
  5. Joint Nasogastric Tube Versus Traditional Decompression Nasogastric Tube to Guided OGT-Overlap Esophagojejunostomy in Laparoscopic Total Gastrectomy: A Randomized Controlled Trial.2025Annals of surgical oncologyRCT
  6. Molecular mechanisms of transmitted endoplasmic reticulum stress mediating immune escape of gastric cancer via PVR overexpression in TAMs.2025Biochimica et biophysica acta. Molecular basis of disease
  7. Association of proteomics with lymph node metastasis in early gastric cancer patients.2025Biochimica et biophysica acta. Molecular basis of disease
  8. Prognostic Performance of the FLAMB Model in Primary Gastric Diffuse Large B-Cell Lymphoma.2025British journal of hospital medicine (London, England : 2005)
  9. Bi-regional and bi-phasic automated machine learning radiomics for defining metastasis to lesser curvature lymph node stations in gastric cancer.2025Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  10. Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer.2025Cancer research communications免费全文
  11. POU2F1 inhibits miR-29b1/a cluster-mediated suppression of PIK3R1 and PIK3R3 expression to regulate gastric cancer cell invasion and migration.2025Chinese medical journal免费全文
  12. CD44v6-mediated regulation of gastric cancer stem cells: a potential therapeutic target.2025Clinical and experimental medicine免费全文
  13. Noninvasive Assessment of Vascular Endothelial Growth Factor and Prognosis in Gastric Cancer Through Radiomic Features.2025Clinical and translational gastroenterology免费全文
  14. UBAP2L-driven stress granule formation links oxaliplatin resistance to gastric cancer.2025Communications biology免费全文
  15. Repurposing of phosphodiesterase-5 inhibitor sildenafil as a therapeutic agent to prevent gastric cancer growth through suppressing c-MYC stability for IL-6 transcription.2025Communications biology免费全文
  16. First clinical investigation to predict lymphovascular and/or perineural invasion in gastric cancer using 18F-FAPI-42 PET/CT parameters.2025European journal of nuclear medicine and molecular imaging
  17. Impact of nutrition, comorbidity and complication on long term survival in gastric cancer following laparoscopic radical gastrectomy: A 10-year cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  18. Identification of a stromal immunosuppressive barrier orchestrated by SPP1+/C1QC+ macrophages and CD8+ exhausted T cells driving gastric cancer immunotherapy resistance.2025Frontiers in immunology免费全文
  19. The alkylglycerone phosphate synthase sustains the resistance of gastric cancer cells to ferroptosis induced by Apatinib.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  20. PFKFB3 confers cisplatin resistance in gastric cancer by inhibiting ferroptosis through SLC7A11/xCT dephosphorylation.2025International immunopharmacology
  21. Targeting the NAT10/XIST/YAP1 Axis-Mediated Vascular Abnormalization Enhances Immune Checkpoint Blockade in Gastric Cancer.2025International journal of biological sciences免费全文
  22. Identification the Cellular Senescence Associated lncRNA LINC01579 in Gastric Cancer.2025Journal of cellular and molecular medicine免费全文
  23. Imaging Characteristics and Clinical Outcomes in Gastric Cancer with Brain Metastasis: A Propensity Score-Matched Study.2025Journal of gastrointestinal cancer
  24. HOXA9 drives lymphatic metastasis by activating the c-MYC-glycolysis-lactate axis in gastric cancer.2025Journal of translational medicine免费全文
  25. Computational pathology approach for assessment of prognosis and immunotherapy response in pan-gastrointestinal cancer.2025Journal of translational medicine免费全文
  26. N6-methyladenosine RNA modified BAIAP2L2 facilitates extracellular vesicles-mediated chemoresistance transmission in gastric cancer.2025Journal of translational medicine免费全文
  27. Long non-coding RNA-MIR181A1HG acts as an oncogene and contributes to invasion and metastasis in gastric cancer.2025Oncogene免费全文
  28. Dynamic key vascular anatomy dataset for D2 lymph node dissection during laparoscopic gastric cancer surgery.2025Scientific data免费全文
  29. Biomimetic Cascade Nanozyme Catalytic System for the Treatment of Lymph Node Metastasis in Gastric Cancer.2025Small (Weinheim an der Bergstrasse, Germany)
  30. Comparison between cap-aspiration lumpectomy versus endoscopic submucosal dissection for the treatment of small gastric submucosal tumors: a prospective randomized controlled trial.2025Surgical endoscopy
  31. Data-Driven Design of Triple-Targeted Protein Nanoprobes for Multiplexed Imaging of Cancer Lymphatic Metastasis.2024Advanced materials (Deerfield Beach, Fla.)
  32. ASO Author Reflections: Preoperative Noninvasive Prediction of Peritoneal Metastasis in Advanced Gastric Cancer: A 18F-FDG PET/CT Radiomics-Based Multimodality Fusion Model.2024Annals of surgical oncology
  33. 18F-FDG PET/CT Radiomics-Based Multimodality Fusion Model for Preoperative Individualized Noninvasive Prediction of Peritoneal Metastasis in Advanced Gastric Cancer.2024Annals of surgical oncology
  34. Screening and identification of vascular endothelial cell targeting peptide in gastric cancer through novel integrated in vitro and in vivo strategy.2024BMC cancer免费全文
  35. Long-term relative survival of patients with gastric cancer from a large-scale cohort: a period-analysis.2024BMC cancer免费全文
  36. FPR3 reprograms glycolytic metabolism and stemness in gastric cancer via calcium-NFATc1 pathway.2024Cancer letters
  37. Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancer.2024Cancer letters
  38. Dynamic single-cell sequencing unveils the tumor microenvironment evolution of gastric cancer abdominal wall metastases during radiotherapy.2024Cancer science免费全文
  39. HMGB1 in exosomes derived from gastric cancer cells induces M2-like macrophage polarization by inhibiting the NF-κB signaling pathway.2024Cell biology international
  40. POLQ inhibition attenuates the stemness and ferroptosis resistance in gastric cancer cells via downregulation of dihydroorotate dehydrogenase.2024Cell death & disease免费全文
  41. Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer.2024Cell metabolism
  42. LINC02139 interacts with and stabilizes XIAP to regulate cell proliferation and apoptosis in gastric cancer.2024Communications biology免费全文
  43. VENet: Variational energy network for gland segmentation of pathological images and early gastric cancer diagnosis of whole slide images.2024Computer methods and programs in biomedicine
  44. Long-term outcomes of endoscopic therapy versus surgical resection for 2-5 cm gastric gastrointestinal stromal tumors: A population-based comparative study.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  45. Helicobacter pylori CagA-mediated ether lipid biosynthesis promotes ferroptosis susceptibility in gastric cancer.2024Experimental & molecular medicine免费全文
  46. N6-methyladenosine modification of OIP5-AS1 promotes glycolysis, tumorigenesis, and metastasis of gastric cancer by inhibiting Trim21-mediated hnRNPA1 ubiquitination and degradation.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  47. Multitask machine learning-based tumor-associated collagen signatures predict peritoneal recurrence and disease-free survival in gastric cancer.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  48. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer.2024Gut免费全文
  49. Gut microbiota modulate CD8+ T cell immunity in gastric cancer through Butyrate/GPR109A/HOPX.2024Gut microbes免费全文
  50. SCD1 promotes the stemness of gastric cancer stem cells by inhibiting ferroptosis through the SQLE/cholesterol/mTOR signalling pathway.2024International journal of biological macromolecules
  51. Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer.2024Journal for immunotherapy of cancer免费全文
  52. Mutual exclusivity and co-occurrence patterns of immune checkpoints indicate NKG2A relates to anti-PD-1 resistance in gastric cancer.2024Journal of translational medicine免费全文
  53. Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: The TIMES001 trial.2024Med (New York, N.Y.)
  54. BST2 promotes gastric cancer metastasis under the regulation of HOXD9 and PABPC1.2024Molecular carcinogenesis
  55. Epstein-Barr virus deubiquitinating enzyme BPLF1 is involved in EBV carcinogenesis by affecting cellular genomic stability.2024Neoplasia (New York, N.Y.)免费全文
  56. Lactate/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer.2024Oncoimmunology免费全文
  57. Comprehensive assessment of immune context and immunotherapy response via noninvasive imaging in gastric cancer.2024The Journal of clinical investigation免费全文
  58. Macrophage-derived cathepsin L promotes epithelial-mesenchymal transition and M2 polarization in gastric cancer.2024World journal of gastroenterology免费全文
  59. N4-Acetylcytidine Drives Glycolysis Addiction in Gastric Cancer via NAT10/SEPT9/HIF-1α Positive Feedback Loop.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  60. Safety and Efficacy of OGT-Assisted Overlap Oesophagojejunostomy Versus the Traditional Overlap Method in Laparoscopic Total Gastrectomy for Gastric/Gastroesophageal Junction (G/GEJ) Tumours.2023Annals of surgical oncology
  61. ASO Author Reflections: OGT-Assisted Method Made the Overlap Esophagojejunostomy in Laparoscopic Total Gastrectomy Easier.2023Annals of surgical oncology
  62. Development and validation of nomogram of peritoneal metastasis in gastric cancer based on simplified clinicopathological features and serum tumor markers.2023BMC cancer免费全文
  63. Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer.2023Cancer communications (London, England)免费全文
  64. Subsite-specific metastatic organotropism and risk in gastric cancer: A population-based cohort study of the US SEER database and a Chinese single-institutional registry.2023Cancer medicine免费全文
  65. The HOXD9-mediated PAXIP1-AS1 regulates gastric cancer progression through PABPC1/PAK1 modulation.2023Cell death & disease免费全文
  66. Non-invasive tumor microenvironment evaluation and treatment response prediction in gastric cancer using deep learning radiomics.2023Cell reports. Medicine免费全文
  67. The LINC00501-HSP90B1-STAT3 positive feedback loop promotes malignant behavior in gastric cancer cells.2023Cellular signalling
  68. Molecular mechanism of XB130 adaptor protein mediates trastuzumab resistance in gastric cancer.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  69. Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study.2023Journal for immunotherapy of cancer免费全文
  70. Co-expression pattern of SLC transporter genes associated with the immune landscape and clinical outcomes in gastric cancer.2023Journal of cellular and molecular medicine免费全文
  71. Predicting response to immunotherapy in gastric cancer via assessing perineural invasion-mediated inflammation in tumor microenvironment.2023Journal of experimental & clinical cancer research : CR免费全文
  72. Intensive Systematic "Train-the-Trainer" Course as an Effective Strategy to Improve Detection of Early Gastric Cancer: A Multicenter Retrospective Study.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  73. Multi-modal analysis for accurate prediction of preoperative stage and indications of optimal treatment in gastric cancer.2023La Radiologia medica
  74. Epigenetic Modification-Associated Molecular Classification of Gastric Cancer.2023Laboratory investigation; a journal of technical methods and pathology
  75. Clinicopathological significance of  Obg-like ATPase 1 and its association with Snail in gastric cancer.2023Polish journal of pathology : official journal of the Polish Society of Pathologists
  76. Raltitrexed regulates proliferation and apoptosis of HGC-27 cells by upregulating RSK4.2022BMC pharmacology & toxicology免费全文
  77. Inhibition of PFKFB3 in HER2-positive gastric cancer improves sensitivity to trastuzumab by inducing tumour vessel normalisation.2022British journal of cancer免费全文
  78. Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer.2022Cancer research免费全文
  79. PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR/CHK1 signaling in gastric cancer.2022Cell death & disease免费全文
  80. Diabetes mellitus promoted lymph node metastasis in gastric cancer: a 15-year single-institution experience.2022Chinese medical journal免费全文
  81. Endoscopic resection via antral submucosal tunneling for en bloc removal of tumors in the duodenal bulb.2022Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  82. Manganese-containing polydopamine nanoparticles as theranostic agents for magnetic resonance imaging and photothermal/chemodynamic combined ferroptosis therapy treating gastric cancer.2022Drug delivery免费全文
  83. Landscape of exitrons in gastric cancer.2022EBioMedicine免费全文
  84. Circulating tumor cell-associated white blood cell cluster is associated with poor survival of patients with gastric cancer following radical gastrectomy.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  85. Disruption of the CCDC43-FHL1 interaction triggers apoptosis in gastric cancer cells.2022Experimental cell research
  86. Safety and short-term outcomes of laparoscopic surgery for advanced gastric cancer after neoadjuvant immunotherapy: A retrospective cohort study.2022Frontiers in immunology免费全文
  87. Prognostic characteristics and clinical response to immunotherapy targeting programmed cell death 1 for patients with advanced gastric cancer with liver metastases.2022Frontiers in immunology免费全文
  88. Tumor Microenvironment Characterization for Assessment of Recurrence and Survival Outcome in Gastric Cancer to Predict Chemotherapy and Immunotherapy Response.2022Frontiers in immunology免费全文
  89. Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients.2022Frontiers in immunology免费全文
  90. Application value of overlap guiding tube (OGT) in assisting overlap esophagojejunostomy during laparoscopic total gastrectomy for gastric/gastroesophageal junction (G/GEJ) tumors.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  91. Tumor-Targeted Polydopamine-Based Nanoparticles for Multimodal Mapping Following Photothermal Therapy of Metastatic Lymph Nodes.2022International journal of nanomedicine免费全文
  92. An artificial intelligence model to predict survival and chemotherapy benefits for gastric cancer patients after gastrectomy development and validation in international multicenter cohorts.2022International journal of surgery (London, England)
  93. Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer-Reply.2022JAMA surgery
  94. Identification of Malassezia globosa as a Gastric Fungus Associated with PD-L1 Expression and Overall Survival of Patients with Gastric Cancer.2022Journal of immunology research免费全文
  95. Effect of Perioperative Interleukin-6 and Tumor Necrosis Factor-α on Long-Term Outcomes in Locally Advanced Gastric Cancer: Results from the CLASS-01 Trial.2022Journal of immunology researchRCT免费全文
  96. Localized DNA tetrahedrons assisted catalytic hairpin assembly for the rapid and sensitive profiling of small extracellular vesicle-associated microRNAs.2022Journal of nanobiotechnology免费全文
  97. Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti-PD-1 inhibitor plus chemotherapy combination in advanced gastric cancer.2022Journal of translational medicine免费全文
  98. An artificial intelligence method to assess the tumor microenvironment with treatment outcomes for gastric cancer patients after gastrectomy.2022Journal of translational medicine免费全文
  99. CT-based radiomics nomograms for preoperative prediction of diffuse-type and signet ring cell gastric cancer: a multicenter development and validation cohort.2022Journal of translational medicine免费全文
  100. Interferon-induced transmembrane protein 2 promotes epithelial-mesenchymal transition by activating transforming growth factor-β1/small mother against decapentaplegic 2 signaling in gastric cancer.2022Molecular biology reports
  101. Prognostic and predictive value of a pathomics signature in gastric cancer.2022Nature communications免费全文
  102. Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer.2022Nature communications免费全文
  103. The miR-3648/FRAT1-FRAT2/c-Myc negative feedback loop modulates the metastasis and invasion of gastric cancer cells.2022Oncogene免费全文
  104. Advances in Treatment Models of Advanced Gastric Cancer.2022Technology in cancer research & treatment免费全文
  105. Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study.2022The Lancet. Digital health
  106. HMGA1 promotes gastric cancer growth and metastasis by transactivating SUZ12 and CCDC43 expression.2021Aging免费全文
  107. Coexpression of HOXA6 and PBX2 promotes metastasis in gastric cancer.2021Aging免费全文
  108. Development and Validation of a Deep Learning CT Signature to Predict Survival and Chemotherapy Benefit in Gastric Cancer: A Multicenter, Retrospective Study.2021Annals of surgery
  109. Yes associated protein 1 promotes resistance to 5-fluorouracil in gastric cancer by regulating GLUT3-dependent glycometabolism reprogramming of tumor-associated macrophages.2021Archives of biochemistry and biophysics
  110. Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation.2021Autophagy免费全文
  111. Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.2021BMC cancer免费全文
  112. Essential meiotic structure-specific endonuclease1 (EME1) promotes malignant features in gastric cancer cells via the Akt/GSK3B/CCND1 pathway.2021Bioengineered免费全文
  113. Depression accelerates gastric cancer invasion and metastasis by inducing a neuroendocrine phenotype via the catecholamine/β2 -AR/MACC1 axis.2021Cancer communications (London, England)免费全文
  114. USP3 promotes gastric cancer progression and metastasis by deubiquitination-dependent COL9A3/COL6A5 stabilisation.2021Cell death & disease免费全文
  115. miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer.2021Cell death & disease免费全文
  116. Identification and validation of methylated differentially expressed miRNAs and immune infiltrate profile in EBV-associated gastric cancer.2021Clinical epigenetics免费全文
  117. A novel through-the-scope twin clip traction-assisted endoscopic submucosal dissection in an in vitro pig stomach model.2021Endoscopy
  118. Apatinib induced ferroptosis by lipid peroxidation in gastric cancer.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  119. Tumor-infiltrating B cell is associated with the control of progression of gastric cancer.2021Immunologic research
  120. Association of Tumor-Associated Collagen Signature With Prognosis and Adjuvant Chemotherapy Benefits in Patients With Gastric Cancer.2021JAMA network open免费全文
  121. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer.2021Journal for immunotherapy of cancer免费全文
  122. Vitamin-B12-conjugated PLGA-PEG nanoparticles incorporating miR-532-3p induce mitochondrial damage by targeting apoptosis repressor with caspase recruitment domain (ARC) on CD320-overexpressed gastric cancer.2021Materials science & engineering. C, Materials for biological applications
  123. LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM.2021Molecular cancer免费全文
  124. Predicting postoperative peritoneal metastasis in gastric cancer with serosal invasion using a collagen nomogram.2021Nature communications免费全文
  125. CRIP1 cooperates with BRCA2 to drive the nuclear enrichment of RAD51 and to facilitate homologous repair upon DNA damage induced by chemotherapy.2021Oncogene免费全文
  126. The Poor Prognosis of Patients with Stage III Gastric Cancer after D2 Dissection Is Mainly due to Lymphatic Metastasis, Especially the Metastasis of No.12a LN: A Nested Case-Control Study.2021Oncology research and treatment
  127. Radiomics signature based on computed tomography images for the preoperative prediction of lymph node metastasis at individual stations in gastric cancer: A multicenter study.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
中文论文(未计入)10
  1. [68Ga-DOTATATE and 18F-FDG PET/CT dual-modality imaging enhances precision of staging and treatment decision for gastroenteropancreatic neuroendocrine neoplasms].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  2. [A retrospective study on the impact of the number of examined lymph nodes on the survival prognosis of patients with N3b gastric cancer].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Effect of preoperative immune checkpoint inhibitors on reducing residual lymph node metastases in patients with gastric cancer: a retrospective study].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [ARL67156, a small-molecule CD39 inhibitor, enhances natural killer cell cytotoxicity against gastric cancer cells in vitro and in nude mice].2023Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  5. [Application of intraoperative endoscopic in laparoscopic gastric cancer surgery].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Cuprous oxide nanoparticles-based photothermal and chemodynamic synergistic therapy inhibits proliferation and migration of gastric cancer cells in vitro].2022Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  7. [Application and progress of artificial intelligence technology in gastric cancer diagnosis and treatment].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Safety and effectiveness of esophagojejunostomy through extracorporeal versus intracorporeal methods after laparoscopic total gastrectomy].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Research progress and prospect of gastric cancer surgery in 2021].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  10. [Shifting paradigm toward minimally invasive gastrectomy for gastric cancer--China's contribution].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)48
  1. Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer即将招募NCT07511894牵头方II期2026-05 启动
  2. Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma即将招募NCT07603349牵头方II/III期2026-06 启动
  3. An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma邀请入组NCT07274579牵头方2025-10 启动
  4. Novel Humanized Ferritin-Based NIR Fluorescent Probe for Identifying Sentinel Lymph Node Metastasis in Early Gastric Cancer正在招募NCT07294638牵头方2025-07 启动
  5. A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening正在招募NCT07032961牵头方2025-06 启动
  6. Novel Humanized Ferritin-based NIR Fluorescent Molecular Probe for Identifying Tumor Margins in Gastric Tissue即将招募NCT07276854牵头方2025-12 启动
  7. Correlation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric Cancer正在招募NCT07003334牵头方2025-01 启动
  8. Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial即将招募NCT06310473牵头方II期2024-03 启动
  9. Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore正在招募NCT06157996牵头方II期2024-06 启动
  10. Dual-Port Laparoscopic Distal Gastrectomy for Gastric Cancer正在招募NCT05494086牵头方不分期2022-08 启动
  11. OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method正在招募NCT05450835牵头方不分期2022-09 启动
  12. Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.正在招募NCT04850729牵头方2021-05 启动
  13. Beta-Blockers on Neoadjuvant Immunochemotherapy for Hypertensive Patients With Gastric Cancer进行中,不再招募NCT07622693牵头方2026-05 启动
  14. Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios已完成NCT06848400牵头方不分期2025-04 启动
  15. Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore状态不明NCT06202716牵头方II期2024-04 启动
  16. JNT Versus TNT to Guided OGT-overlap Oesophagojejunostomy已完成NCT06412575牵头方不分期2023-01 启动
  17. Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial状态不明NCT04744649牵头方II期2021-03 启动
  18. Relationship Between Standard Treatment Efficacy and The Tumor Microenvironment in Advanced Gastric Cancer状态不明NCT04850716牵头方2021-04 启动
  19. A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer状态不明NCT04934618牵头方II期2020-05 启动
  20. Safety and Efficacy of OGT Method Versus the Traditional Overlap Method已完成NCT05442502牵头方2018-06 启动
  21. Comparison of Endoscopic and Laparoscopic Resection for Small Gastric Gastrointestinal Stromal Tumor状态不明NCT03471273牵头方不分期2017-09 启动
  22. Radiomics for Prediction of Lymph Node Metastasis in Gastric Cancer(RPLNM)(GIPMCS-1701)状态不明NCT03488446牵头方2017-08 启动
  23. Enhanced Recovery After Surgery (ERAS) on Laparoscopy-assisted Distal Gastrectomy状态不明NCT03016026牵头方II期2016-11 启动
  24. Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis状态不明NCT03023436牵头方III期2016-01 启动
  25. Intracorporeal Versus Extracorporeal Roux-en-Y Esophagojejunostomy During Laparoscopic Total Gastrectomy for Gastric Cancer状态不明NCT02085031牵头方II期2014-04 启动
  26. Laparoscopy-assisted and Open Distal Gastrectomy for Gastric Cancer in the Elderly Patients状态不明NCT02246153牵头方III期2014-09 启动
  27. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)状态不明NCT01609309牵头方III期2012-09 启动
  28. Clinicopathological Features and Treatment Strategies for Gastric Epithelial Neoplasm of Fundic-gland Mucosa Lineage已完成NCT07230054牵头方2010-08 启动
  29. Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma状态不明NCT04058470牵头方(推断)I/II期2020-04 启动
  30. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  31. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  32. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT06155383研究中心II期2023-11 启动
  33. AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy正在招募NCT06035250研究中心2023-09 启动
  34. Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics正在招募NCT05722275研究中心2023-01 启动
  35. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  36. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer已终止NCT05149807研究中心II/III期2022-01 启动
  37. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  38. A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction已完成NCT04661150研究中心II期2021-03 启动
  39. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  40. Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC状态不明NCT04638959研究中心2019-09 启动
  41. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  42. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers状态不明NCT03468712研究中心不分期2018-03 启动
  43. Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer已完成NCT03427814研究中心II期2018-07 启动
  44. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer状态不明NCT02845986研究中心II期2016-09 启动
  45. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  46. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2状态不明NCT02356276研究中心III期2015-05 启动
  47. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动
  48. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年没有牵头肝母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 8 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Downregulation of hepatic lipase is associated with decreased CD133 expression and clone formation in HepG2 cells.2018International journal of molecular medicine

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 8 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.3%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 1120232024: 1120242025: 112025

广州有 33 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科神经外科

这些论文过半是实验室或动物研究。

牵头的论文6
  1. Natural product Eriocalyxin B exerts anti-tumor effects by downregulating TCEA3 expression and sensitizes immune checkpoint blockade therapy in osteosarcoma.2025Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  2. Imaging diagnosis and differential diagnosis of extraskeletal osteosarcoma.2024BMC cancer
  3. A rare case of long venous tumor thrombi from the right femoral vein to the right ventricle visualized by [18F]-FDG PET/CT in a patient with chondrogenic osteosarcoma.2023European journal of nuclear medicine and molecular imaging
  4. Tribbles Pseudokinase 2 Promotes the Proliferation, Migration, and Invasion of Osteosarcoma through Modulating AP4/p21 Pathway.2022Annals of clinical and laboratory science
  5. Individualized combination therapies based on whole-exome sequencing displayed significant clinical benefits in a glioblastoma patient with secondary osteosarcoma: case report and genetic characterization.2022BMC neurology
  6. Identification and validation of miR-509-5p as a prognosticator for favorable survival in osteosarcoma.2022Medicine
早期论文(2016–2020 年)9
  1. Head and neck osteosarcoma: CT and MR imaging features.2020Dento maxillo facial radiology
  2. CT and MRI features of calvarium and skull base osteosarcoma (CSBO).2020The British journal of radiology
  3. lncRNA SNHG1 negatively regulates miRNA‑101‑3p to enhance the expression of ROCK1 and promote cell proliferation, migration and invasion in osteosarcoma.2019International journal of molecular medicine
  4. Dysregulated circRNA_100876 suppresses proliferation of osteosarcoma cancer cells by targeting microRNA-136.2019Journal of cellular biochemistry
  5. The extremity localized classic osteosarcomas have better survival than the axial non-classics.2018World journal of surgical oncology
  6. miR-451 inhibits cell growth, migration and angiogenesis in human osteosarcoma via down-regulating IL 6R.2017Biochemical and biophysical research communications
  7. MiR-451 suppresses proliferation, migration and promotes apoptosis of the human osteosarcoma by targeting macrophage migration inhibitory factor.2017Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  8. Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7.2017Clinical and experimental medicine
  9. Knockdown of UBE2T Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion by Suppressing the PI3K/Akt Signaling Pathway.2016Oncology research

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

广州有 13 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科
牵头的论文2
  1. Comparison between cap-aspiration lumpectomy versus endoscopic submucosal dissection for the treatment of small gastric submucosal tumors: a prospective randomized controlled trial.2025Surgical endoscopy
  2. Long-term outcomes of endoscopic therapy versus surgical resection for 2-5 cm gastric gastrointestinal stromal tumors: A population-based comparative study.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
早期论文(2016–2020 年)14
  1. Laparoscopic resection is better than endoscopic dissection for gastric gastrointestinal stromal tumor between 2 and 5 cm in size: a case-matched study in a gastrointestinal center.2020Surgical endoscopy
  2. Developed and validated a prognostic nomogram for recurrence-free survival after complete surgical resection of local primary gastrointestinal stromal tumors based on deep learning.2019EBioMedicine
  3. A new nomogram for recurrence-free survival prediction of gastrointestinal stromal tumors: Comparison with current risk classification methods.2019European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  4. The roles of CT and EUS in the preoperative evaluation of gastric gastrointestinal stromal tumors larger than 2 cm.2019European radiology
  5. Radiomics nomogram for predicting the malignant potential of gastrointestinal stromal tumours preoperatively.2019European radiology
  6. Performance of risk stratification systems for gastrointestinal stromal tumors: A multicenter study.2019World journal of gastroenterology
  7. Effectiveness and safety of endoscopic resection for gastric GISTs: a systematic review.2018Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  8. Comparison of endoscopic submucosal tunneling dissection and thoracoscopic enucleation for the treatment of esophageal submucosal tumors.2017Gastrointestinal endoscopy
  9. Meta-analysis of laparoscopic vs. open resection of gastric gastrointestinal stromal tumors.2017PloS one
  10. Safety analysis of laparoscopic endoscopic cooperative surgery versus endoscopic submucosal dissection for selected gastric gastrointestinal stromal tumors: a propensity score-matched study.2017Surgical endoscopy
  11. Retrospective study of laparoscopic versus open gastric resection for gastric gastrointestinal stromal tumors based on the propensity score matching method.2017Surgical endoscopy
  12. Laparoscopic management of gastric gastrointestinal stromal tumors: A retrospective 10-year single-center experience.2017World journal of gastroenterology
  13. [Comparison of modified NIH and AFIP risk-stratification criteria for gastrointestinal stromal tumors: A multicenter retrospective study].2017Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  14. Endoscopic band ligation versus endoscopic submucosal dissection and laparoscopic resection for small gastric stromal tumors.2016Surgical endoscopy
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Comparison of Endoscopic and Laparoscopic Resection for Small Gastric Gastrointestinal Stromal Tumor状态不明NCT03471273牵头方不分期2017-09 启动
  2. ESTD vs. VATS for Upper Gastrointestinal Submucosal Tumors状态不明NCT01768104牵头方不分期2011-12 启动
  3. Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study状态不明NCT05440357研究中心2022-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

广州有 23 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.2%。

牵头论文
3
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

广州有 14 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07555938

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南京、天津、广州、昆明、杭州、武汉、济南、温州、苏州、青岛

  2. 正在招募
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
    分期
    I期
    开始
    2025-12
    登记号
    NCT07179679

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、南京、南充、南昌、广州、承德、苏州、西安、重庆

  3. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

  4. 正在招募
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    分期
    III期
    开始
    2022-11
    登记号
    NCT05623020

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、天津、广州、杭州、武汉、温州、福州、苏州、长春

  5. 正在招募
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    分期
    III期
    开始
    2021-10
    登记号
    NCT05020236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层干细胞移植
牵头的论文3
  1. Low peripheral blood B lymphocyte count predicts poor outcome in patients with multiple myeloma.2025Immunobiology
  2. Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments.2023Annals of hematology免费全文
  3. CD43 is an adverse prognostic factor in newly diagnosed multiple myeloma.2022Leukemia & lymphoma
中文论文(未计入)1
  1. [Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)21
  1. Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT状态不明NCT03385096牵头方II/III期2018-01 启动
  2. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma正在招募NCT07555938研究中心III期2026-06 启动
  3. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors正在招募NCT07179679研究中心I期2025-12 启动
  4. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant正在招募NCT05623020研究中心III期2022-11 启动
  5. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  6. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments正在招募NCT05020236研究中心III期2021-10 启动
  7. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  8. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  9. Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma状态不明NCT05422027研究中心I/II期2022-07 启动
  10. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  11. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.已完成NCT05228470研究中心II期2021-12 启动
  12. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  13. A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma已完成NCT04121260研究中心I期2019-12 启动
  14. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03860038研究中心II期2019-01 启动
  15. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma已完成NCT03944057研究中心II期2019-09 启动
  16. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  17. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  18. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动
  19. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)已终止NCT01947309研究中心2013-11 启动
  20. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year已完成NCT02348528研究中心II期2012-09 启动
  21. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma已完成NCT01593410研究中心II期2010-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 8 篇,占 3.6%。

牵头论文
8
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 4420242025: 222025

广州有 8 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-01
    登记号
    NCT06764238

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 24 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、深圳、福州、苏州、西安、贵阳、重庆、长沙、青岛

  2. 正在招募
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-03
    登记号
    NCT06882057

    年龄 1 岁 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 23 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、福州、苏州、西安、贵阳、重庆、长沙、青岛

  3. 正在招募
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    分期
    III期
    开始
    2025-03
    登记号
    NCT07152041

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 20 家列出的医院为研究中心上海、南京、南昌、天津、广州、成都、武汉、济南、深圳、福州、苏州、贵阳、重庆、长沙、青岛

  4. 正在招募
    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
    分期
    I/II期
    开始
    2023-02
    登记号
    NCT05667506

    年龄 3 岁 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心南京、南昌、合肥、天津、广州、徐州、武汉、重庆

  5. 正在招募
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    分期
    I/II期
    开始
    2022-11
    登记号
    NCT05579132

    年龄 2 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心天津、广州、徐州、成都、杭州、武汉、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题费城染色体与遗传学儿童微小残留病与复发
论文中的科室儿科
牵头的论文8
  1. Integrating bulk RNA-seq and scRNA-seq data to explore diverse cell death patterns and develop a programmed cell death-related relapse prediction model in pediatric B-ALL.2025Scientific reports免费全文
  2. Refining Risk Stratification for B-cell Precursor Adult Acute Lymphoblastic Leukemia Treated With a Pediatric-inspired Regimen by Combining IKZF1 Deletion and Minimal Residual Disease.2025Transplantation and cellular therapy
  3. A meta-analysis of the prognostic significance of CDKN deletions in acute lymphoblastic leukaemia.2024Annals of medicine免费全文
  4. STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult B-cell acute lymphoblastic leukaemia.2024British journal of haematology
  5. PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.2024British journal of haematology
  6. Dynamic evolution of bone marrow adipocyte in B cell acute lymphoblastic leukemia: insights from diagnosis to post-chemotherapy.2024Cancer biology & therapy
  7. Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia.2022Bone marrow transplantation
  8. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.2022Hematology (Amsterdam, Netherlands)
中文论文(未计入)1
  1. [Prognostic significance of IKZF1 gene deletions in patients with B-cell acute lymphoblastic leukemia].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. Induced-T Cell Like NK Cells for B Cell Malignancies状态不明NCT04747093牵头方I/II期2021-01 启动
  2. Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL状态不明NCT03564470牵头方II/III期2016-02 启动
  3. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol正在招募NCT06764238研究中心II/III期2025-01 启动
  4. Newly-diagnosed Pediatric Ph-positive B-ALL Protocol正在招募NCT07152041研究中心III期2025-03 启动
  5. Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol正在招募NCT06882057研究中心II/III期2025-03 启动
  6. A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)正在招募NCT05667506研究中心I/II期2023-02 启动
  7. A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)正在招募NCT05579132研究中心I/II期2022-11 启动
  8. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL进行中,不再招募NCT04521231研究中心I/II期2021-01 启动
  9. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)已完成NCT03476239研究中心III期2017-10 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 21 篇,占 6.7%。

牵头论文
21
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 3320232024: 7720242025: 882025

广州有 23 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
    分期
    II期
    开始
    2019-11
    登记号
    NCT04143724

    年龄 6 岁 至 17 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心南宁、广州、成都、深圳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室儿科病理/检验科
牵头的论文21
  1. Haplotype-Resolved Genotyping and Association Analysis of 1,020 β-Thalassemia Patients by Targeted Long-Read Sequencing.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  2. Rapid detection of genetic modifiers of β-thalassemia based on MALDI-TOF MS.2025Annals of hematology
  3. Mutations in AMBRA1 aggravate β-thalassemia by impairing autophagy-mediated clearance of free α-globin.2025Blood
  4. A common TBP-binding site mutation elevates fetal hemoglobin levels by competitive globin switching change in β-thalassemia.2025Blood advances
  5. Whole-genome Sequencing Association Analysis of Quantitative Platelet Traits in A Large Cohort of β-thalassemia.2025Genomics, proteomics & bioinformatics
  6. A Chinese pediatric patient with thalassemia traits and compound heterozygous mutations in the PIEZO1 gene suspected of having dehydrated hereditary stomatocytosis.2025Hematology (Amsterdam, Netherlands)
  7. Identification of a Patient with Transfusion-Dependent β-Thalassemia Caused by Compound Heterozygous Mutations of HBB: C.84_85insC and Common Linked Intronic Variants in HBB.2025Hemoglobin
  8. Activation of γ-globin expression by a common variant disrupting IKAROS-binding motif in β-thalassemia.2025Journal of genetics and genomics = Yi chuan xue bao
  9. Identification and characterization of CHD4-associated eRNA as a novel modulator of fetal hemoglobin levels in β-thalassemia.2024Biochemical and biophysical research communications
  10. Characterization of a novel 8.2 kb deletion causing beta-thalassemia.2024Clinical biochemistry
  11. Activation of γ-globin expression by LncRNA-mediated ERF promoter hypermethylation in β-thalassemia.2024Clinical epigenetics
  12. SUPT5H mutations associated with elevation of Hb A2 level: Identification of two novel variants and literature review.2024Gene
  13. An unusual case of thalassemia intermedia with inheritable complex repeats detected by single-molecule optical mapping.2024Haematologica
  14. Prevalence of thalassaemia among childbearing-age Li and Han populations in Hainan Province.2024Hematology (Amsterdam, Netherlands)
  15. Safety and efficacy of peripheral blood stem cells collection in healthy children and pediatric patients with thalassemia major weighing 20 kg or less.2024Journal of clinical apheresis
  16. The Effect of Iron Overload on the Mobilization of Peripheral Blood Hematopoietic Stem Cells in Pediatric Patients with Thalassemia Major.2023Acta haematologica
  17. A novel gain-of-function PIP4K2A mutation elevates the expression of β-globin and aggravates the severity of α-thalassemia.2023British journal of haematology
  18. Target-allele-specific probe single-base extension (TASP-SBE): a novel MALDI-TOF-MS strategy for multi-variants analysis and its application in simultaneous detection of α-/β-thalassemia mutations.2023Human geneticsRCT
  19. Iron parameters in pregnant women with beta-thalassaemia minor combined with iron deficiency anaemia compared to pregnant women with iron deficiency anaemia alone demonstrate the safety of iron supplementation in beta-thalassaemia minor dur2022British journal of haematology
  20. MALDI-TOF-MS for Rapid Screening and Typing of β-Globin Variant and β-Thalassemia through Direct Measurements of Intact Globin Chains.2022Clinical chemistry
  21. TEA domain transcription factor 4 modulates repression of fetal haemoglobin by direct binding to the γ-globin gene promoters.2021British journal of haematology
早期论文(2016–2020 年)6
  1. Long-term results of the NF-08-TM protocol in stem cell transplant for patients with thalassemia major: A multi-center large-sample study.2020American journal of hematology
  2. Oridonin enhances γ‑globin expression in erythroid precursors from patients with β‑thalassemia via activation of p38 MAPK signaling.2020Molecular medicine reports
  3. Related and unrelated donor transplantation for β-thalassemia major: results of an international survey.2019Blood advances
  4. Non-invasive prenatal testing for fetal inheritance of maternal β-thalassaemia mutations using targeted sequencing and relative mutation dosage: a feasibility study.2018BJOG : an international journal of obstetrics and gynaecology
  5. Genetic diagnosis of polycystic kidney disease, Alport syndrome, and thalassemia minor in a large Chinese family.2017Clinical science (London, England : 1979)
  6. [Nosocomial septicemia in the early stage after stem cell transplantation in children with major β-thalassemia].2016Nan fang yi ke da xue xue bao = Journal of Southern Medical University
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Evaluation of Heart Status in Patients of Beta Thalassemia Using Echocardiogram状态不明NCT04929574牵头方2021-07 启动
  2. Association of Hb F Level With Clinical Severity of Beta Thalassemia状态不明NCT04917978牵头方2019-12 启动
  3. Genetic Variants Affecting the Clinical Severity of Beta Thalassemia状态不明NCT04918056牵头方2017-01 启动
  4. Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified状态不明NCT03276455牵头方I/II期2017-09 启动
  5. Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major状态不明NCT02126046牵头方不分期2012-09 启动
  6. Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia正在招募NCT04143724研究中心II期2019-11 启动
  7. Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia进行中,不再招募NCT05577312研究中心I/II期2022-11 启动
  8. A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia已终止NCT04925206研究中心I期2021-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 9 篇,占 3.3%。

牵头论文
9
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 1120222023: 1120232024: 0020242025: 222025

广州有 8 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
    分期
    III期
    开始
    2026-04
    登记号
    NCT07416604

    年龄 12 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、天津、广州、福州

  2. 正在招募
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    分期
    III期
    开始
    2025-03
    登记号
    NCT06833983

    年龄 18 岁 至 65 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心兰州、北京、南京、南昌、合肥、唐山、天津、广州、昆明、武汉、济南、郑州、长沙

  3. 正在招募
    Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
    分期
    III期
    开始
    2021-11
    登记号
    NCT05145127

    年龄 1 岁 至 74 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南昌、天津、广州、武汉、贵阳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室儿科病理/检验科
牵头的论文9
  1. Coagulation Factor Consumption and Medium- to Long-Term Outcomes of Achilles Tendon Lengthening With and Without External Fixation in Haemophilia.2026Haemophilia : the official journal of the World Federation of Hemophilia
  2. Treatment of fracture in haemophilia: a retrospective study.2026International orthopaedics
  3. Efficacy and Safety of Recombinant Factor VIII in Previously Untreated and Previously Treated Children with Hemophilia A: A Systematic Review.2025Advances in therapy
  4. Application of capillary gel electrophoresis in detection of Factor VIII gene intron 22 inversion of hemophilia A.2025Journal of hematopathology
  5. Relationship between serum cartilage turnover biomarkers and haemophilic arthropathy severity in adult patients with severe haemophilia A in China.2023Haemophilia : the official journal of the World Federation of Hemophilia
  6. Value of Contrast-enhanced Ultrasound in Evaluating Synovitis and Predicting Recurrent Joint Bleeding of Hemophilia.2022Current medical science
  7. Surgical treatment for patients with hemophilic pseudotumor-related femoral fracture: a retrospective study.2021Journal of orthopaedic surgery and research
  8. Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review.2021Orphanet journal of rare diseases
  9. The spectrum of FVIII gene variants detected by next generation sequencing in 236 Chinese non-inversion hemophilia A pedigrees.2021Thrombosis research
中文论文(未计入)1
  1. [Effect of FVIII doses on joint structure and function in adolescents with severe hemophilia A: mid-term results of a prospective cohort study].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical University
早期论文(2016–2020 年)11
  1. Target capture next-generation sequencing in non-inversion haemophilia: an alternative approach.2020British journal of haematology
  2. Treatment of pelvic haemophilic pseudotumour: A retrospective study.2020Haemophilia : the official journal of the World Federation of Hemophilia
  3. Clinical characteristics and surgical treatment of haemophilic pseudotumor: A retrospective analysis of thirty-four patients.2020Haemophilia : the official journal of the World Federation of Hemophilia
  4. Intracranial Hemorrhage in Children With Inherited Bleeding Disorders: A Single Center Study in China.2019Journal of pediatric hematology/oncology
  5. [Efficacy of short-term full-dose prophylaxis in adult Chinese patients with severe hemophilia A].2018Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  6. [Prophylactic treatment with low- and intermediate-dose factor VIII in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis].2018Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  7. The demographics, treatment characteristics and quality of life of adult people with haemophilia in China - results from the HERO study.2017Haemophilia : the official journal of the World Federation of Hemophilia
  8. [Breakthrough bleeding in adult patients with severe hemophilia A receiving low- and intermediate-dose FVIII for tertiary prophylaxis: characteristics and influencing factors].2017Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  9. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.2017Pediatric hematology and oncology
  10. Haemophilic pseudotumour with fistulae formation: a retrospective report of five infected cases.2016Haemophilia : the official journal of the World Federation of Hemophilia
  11. [Modified Bethesda, modified Nijmegen and blank assays for coagulation factor VIII inhibitor detection and factors affecting the results].2016Nan fang yi ke da xue xue bao = Journal of Southern Medical University
它在 ClinicalTrials.gov 上的全部试验(任何状态)26
  1. A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A正在招募NCT07416604研究中心III期2026-04 启动
  2. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A正在招募NCT06833983研究中心III期2025-03 启动
  3. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors正在招募NCT05145127研究中心III期2021-11 启动
  4. Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A即将招募NCT06136507研究中心III期2026-12 启动
  5. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.进行中,不再招募NCT07684898研究中心III期2026-06 启动
  6. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment进行中,不再招募NCT07663903研究中心III期2026-04 启动
  7. Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products已完成NCT06738485研究中心III期2025-01 启动
  8. A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A进行中,不再招募NCT06297655研究中心III期2024-11 启动
  9. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A已完成NCT05707351研究中心III期2023-03 启动
  10. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A进行中,不再招募NCT05685238研究中心III期2023-02 启动
  11. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein已完成NCT06142552研究中心III期2023-12 启动
  12. A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B正在招募NCT05611801研究中心III期2022-12 启动
  13. Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor状态不明NCT05487976研究中心III期2022-04 启动
  14. A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors已完成NCT05306418研究中心III期2022-04 启动
  15. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)已完成NCT05082116研究中心III期2021-09 启动
  16. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A已完成NCT04845399研究中心III期2021-04 启动
  17. A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection已完成NCT04864743研究中心I期2021-06 启动
  18. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors已完成NCT05053139研究中心III期2021-12 启动
  19. A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ,Fc Fusion Protein for Injection已完成NCT05251090研究中心I期2021-06 启动
  20. Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B已完成NCT03938792研究中心III期2020-03 启动
  21. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.已完成NCT04456387研究中心III期2020-10 启动
  22. A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection状态不明NCT03747653研究中心2019-03 启动
  23. Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants已完成NCT03315455研究中心III期2018-04 启动
  24. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A已完成NCT02492984研究中心IV期2015-04 启动
  25. A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment已完成NCT02476942研究中心2015-05 启动
  26. ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)已完成NCT02078427研究中心2011-06 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

非典型溶血性尿毒症综合征

Atypical haemolytic uraemic syndrome

2021–2025 年中国大陆作者发表的 27 篇非典型溶血性尿毒症综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

广州有 1 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。

这些数字背后的记录
论文中的科室儿科
牵头的论文1
  1. Cyclosporine A relieved proteinuria and hypoproteinemia in DGKE nephropathy.2021Clinica chimica acta; international journal of clinical chemistry

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

广州有 9 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。

这些数字背后的记录
研究主题抗体与诊断
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

广州有 8 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06447597

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、广州、成都、杭州、武汉、济南、西安、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题胸腺与胸腺切除

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.7%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 2220232024: 0020242025: 112025

广州有 3 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题血管重建手术影像与脑血流遗传
论文中的科室神经外科影像/核医学科
牵头的论文6
  1. Multiple arachnoid membrane opening to promote angiogenesis in adult patients with moyamoya disease after combined bypass surgery: a multicenter randomized controlled clinical trial.2026Journal of neurosurgeryRCT
  2. miR-6760-5p suppresses neoangiogenesis by targeting Yes-associated protein 1 in patients with moyamoya disease undergoing indirect revascularization.2025Gene
  3. Is STA really a low-flow graft? A quantitative ultrasonographic study of the flow of STA for cerebral revascularization in MMD patients.2023CNS neuroscience & therapeutics免费全文
  4. Association of Cerebral Hemodynamics and Cognitive Function in Adult Patients with Moyamoya Disease: A Three-Dimensional Pseudo-Continuous Arterial Spin Labeling Study.2023World neurosurgery
  5. A Preliminary Report of One-Session Treatment with Cranioplasty and Superficial Temporal Artery-Middle Cerebral Artery Bypass for Hemorrhagic Moyamoya Disease Patients with Skull Defect.2022World neurosurgery
  6. Use of a panel of four microRNAs in CSF as a predicted biomarker for postoperative neoangiogenesis in moyamoya disease.2021CNS neuroscience & therapeutics免费全文
中文论文(未计入)1
  1. [Three-dimensional pseudo-continuous arterial spin labeling for evaluation of cerebral hemodynamic changes after revascularization in adult patients with moyamoya disease].2023Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
PubMed 以外找到的论文(未计入)3
  1. miR-486-3p ameliorates aging-related impaired angiogenesis in adult moyamoya disease by targeting Forkhead Box O42025bioRxiv (Cold Spring Harbor Laboratory)预印本
  2. miR-6760-5p suppresses neoangiogenesis by targeting Yes-associated protein 1 in patients with moyamoya disease undergoing indirect revascularization2024Research Square预印本
  3. Moyamoya Disease Manifesting as Paroxysmal Kinesigenic Dystonia: A Case Report and Literature Review2023Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 7 篇,占 2.6%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 0020222023: 1120232024: 1120242025: 112025

广州有 12 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科

这些论文过半是实验室或动物研究。

牵头的论文7
  1. Chaihu Guizhi Decoction prevents cognitive, memory impairments and sensorimotor gating deficit induced by N-methyl-d-aspartate receptor antibody in mice.2025Journal of ethnopharmacology
  2. Exploring the neuroprotective role of artesunate in mouse models of anti-NMDAR encephalitis: insights from molecular mechanisms and transmission electron microscopy.2024Cell communication and signaling : CCS
  3. Multi-proteomic Analysis Revealed Distinct Protein Profiles in Cerebrospinal Fluid of Patients Between Anti-NMDAR Encephalitis NORSE and Cryptogenic NORSE.2023Molecular neurobiology
  4. Clinical analysis of five case reports of ovarian teratoma withanti-N-methyl-D-aspartate receptor encephalitis.2021Annals of palliative medicine
  5. High Level of Soluble CD146 In Cerebrospinal Fluid Might be a Biomarker of Severity of Anti-N-Methyl-D-Aspartate Receptor Encephalitis.2021Frontiers in immunology
  6. Paroxysmal Sympathetic Hyperactivity in Severe Anti-N-Methyl-d-Aspartate Receptor Encephalitis: A Single Center Retrospective Observational Study.2021Frontiers in immunology
  7. Anti-NMDAR encephalitis induced in mice by active immunization with a peptide from the amino-terminal domain of the GluN1 subunit.2021Journal of neuroinflammation
早期论文(2016–2020 年)10
  1. A refractory anti-NMDA receptor encephalitis successfully treated by bilateral salpingo-oophorectomy and intrathecal injection of methotrexate and dexamethasone: a case report.2020The Journal of international medical research
  2. Clinical significance of soluble adhesion molecules in anti-NMDAR encephalitis patients.2019Annals of clinical and translational neurology
  3. Cerebrospinal fluid light and heavy neurofilament level increased in anti-N-methyl-d-aspartate receptor encephalitis.2019Brain and behavior
  4. Higher CSF Levels of NLRP3 Inflammasome Is Associated With Poor Prognosis of Anti-N-methyl-D-Aspartate Receptor Encephalitis.2019Frontiers in immunology
  5. Cell-Free Mitochondrial DNA in the CSF: A Potential Prognostic Biomarker of Anti-NMDAR Encephalitis.2019Frontiers in immunology
  6. The HMGB1 is increased in CSF of patients with an Anti-NMDAR encephalitis.2018Acta neurologica Scandinavica
  7. Elevated neuron-specific enolase and S100 calcium-binding protein B concentrations in cerebrospinal fluid of patients with anti-N-methyl-d-aspartate receptor encephalitis.2018Clinica chimica acta; international journal of clinical chemistry
  8. Cerebrospinal fluid pentraxin 3 and CD40 ligand in anti-N-menthyl-d-aspartate receptor encephalitis.2018Journal of neuroimmunology
  9. Anti-N-methyl-D-aspartate receptor encephalitis associated with intracranial Angiostrongylus cantonensis infection: a case report.2017Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  10. Heterotopic ossification following anti-NMDA receptor encephalitis: a case report.2016BMC neurology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.5%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025

广州有 20 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

这些论文过半是实验室或动物研究。

牵头的论文5
  1. Bioinformatics-based identification of mirdametinib as a potential therapeutic target for idiopathic pulmonary fibrosis associated with endoplasmic reticulum stress.2025Naunyn-Schmiedeberg's archives of pharmacology
  2. Tetrandrine alleviates pulmonary fibrosis by inhibiting alveolar epithelial cell senescence through PINK1/Parkin-mediated mitophagy.2024European journal of pharmacology
  3. RNF130 protects against pulmonary fibrosis through suppressing aerobic glycolysis by mediating c-myc ubiquitination.2023International immunopharmacology
  4. Extracellular HSP90α promotes cellular senescence by modulating TGF-β signaling in pulmonary fibrosis.2022FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  5. SIRT1 prevents cigarette smoking-induced lung fibroblasts activation by regulating mitochondrial oxidative stress and lipid metabolism.2022Journal of translational medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  2. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis已终止NCT06097260研究中心II期2023-11 启动
  3. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05938920研究中心II期2023-06 启动
  4. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04552899研究中心III期2021-03 启动
  5. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)已终止NCT03955146研究中心III期2019-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.8%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 2220242025: 112025

广州有 13 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年中国大陆作者发表的 55 篇脊髓性肌萎缩症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.8%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

广州有 2 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

广州有 3 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年没有牵头杜氏肌营养不良的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 7 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年没有牵头Alport 综合征的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 5 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Genetic diagnosis of polycystic kidney disease, Alport syndrome, and thalassemia minor in a large Chinese family.2017Clinical science (London, England : 1979)

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.7%。

牵头论文
5
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 2220232024: 0020242025: 112025

广州有 20 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
    分期
    IV期
    开始
    2026-06
    登记号
    NCT07604311

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科肾内科
牵头的论文5
  1. Association of urinary LIF levels with disease prognosis and treatment response to methylprednisolone in IgA nephropathy.2025Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  2. Immunosuppression versus Supportive Care on Kidney Outcomes in IgA Nephropathy in the Real-World Setting.2023Clinical journal of the American Society of Nephrology : CJASN
  3. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial.2023JAMA network openRCT
  4. Orange-derived and dexamethasone-encapsulated extracellular vesicles reduced proteinuria and alleviated pathological lesions in IgA nephropathy by targeting intestinal lymphocytes.2022Frontiers in immunology
  5. Intensity of Macrophage Infiltration in Glomeruli Predicts Response to Immunosuppressive Therapy in Patients with IgA Nephropathy.2021Journal of the American Society of Nephrology : JASN
中文论文(未计入)1
  1. [The comorbidity mechanism of celiac disease and immunoglobulin A nephropathy].2025Zhonghua nei ke za zhi
早期论文(2016–2020 年)2
  1. Kidney Biopsies in Elderly Chinese Patients: A Nationwide Survey.2020American journal of kidney diseases : the official journal of the National Kidney Foundation
  2. Urinary Matrix Metalloproteinase 7 and Prediction of IgA Nephropathy Progression.2020American journal of kidney diseases : the official journal of the National Kidney Foundation
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy正在招募NCT07604311牵头方IV期2026-06 启动
  2. The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients已完成NCT01854814牵头方(推断)不分期2013-07 启动
  3. A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.已完成NCT05016323研究中心II期2021-09 启动
  4. Atrasentan in Patients With IgA Nephropathy进行中,不再招募NCT04573478研究中心III期2020-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

广州有 9 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性膈疝

Congenital diaphragmatic hernia

2021–2025 年中国大陆作者发表的 60 篇先天性膈疝 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 4 家医院列在先天性膈疝下全国有 46 家医院列在先天性膈疝下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年没有牵头先天性巨结肠的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 8 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Laparoscopic Redo Pull-Through for Hirschsprung Disease Due to Innervation Disorders.2019Journal of laparoendoscopic & advanced surgical techniques. Part A

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

广州有 6 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

南方医科大学南方医院

Nanfang Hospital

广州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Nanfang Hospital of Southern Medical University; Southern Medical University Nanfang Hospital; Nanfang Hospital Affiliated to Southern Medical University; NanFang Hospital; Nanfang Hospital (L. Li; Departmen of General Surgery Nanfang Hospital; Nanfang Hospital and Basic Medical College; Ganzhou Hospital-Nanfang Hospital

提出更正下载数据